Hospital del Trabajador Santiago: The NCT Campus String Is Not the ISP File

Figures cited from a ClinicalTrials.gov LATAM facility sweep (API pull 1 September 2026, 6:32 PM ET) and published bioaccess® country pages. Registry ranking is not a bioaccess® claim that we ran any of these studies. General information, not legal or regulatory advice. Confirm current ISP, ethics, and FDA rules with qualified advisers. We name only the facility strings and example NCT IDs those sources support. We do not invent a principal investigator. We do not claim Hospital del Trabajador Santiago as a bioaccess® client.

If you searched Hospital del Trabajador Santiago first-in-human, Hospital del Trabajador de Santiago clinical trial, Asociación Chilena de Seguridad hospital CRO, or “go direct Hospital del Trabajador Santiago,” you followed a campus string ClinicalTrials.gov still publishes. Hospital del Trabajador in Santiago, Chile, is a real named trauma/occupational hospital-campus string on ClinicalTrials.gov (aliases include Hospital del Trabajador, Hospital del Trabajador de Santiago, Hospital del Trabajador de la Asociación Chilena de Seguridad). It is not a first-in-human medical-device CRO, and it is not the operator of the ISP file.

bioaccess®’s position is simple and it is not adversarial: the hospital is the site. The First-in-Human CRO still owns ISP, accredited ethics, investigational import, insurance, ISO 14155 monitoring, and the FDA 21 CFR 812.28 package — plus the option to add Colombia or another Latin American country if this campus is not the only fit. Sponsors who skip the CRO and email the hospital still have to rebuild that stack. An NCT location row is not a CRO.

This page is the named Santiago Hospital del Trabajador campus. It is DISTINCT from Clínica Colonial Santiago, Clínica Alemana de Santiago, Clínica Las Condes Santiago, Clínica MEDS La Dehesa Santiago, Hospital FACH Santiago, and Clínica INDISA Santiago. Sharing Santiago metro is not a license to collapse them.

Why the campus name wins the search — and why that is not a CRO

Device registries write the city, the hospital, and a list of NCT IDs. They rarely write the CRO. On the 1 September 2026 ClinicalTrials.gov LATAM sweep (interventional studies; all years; complete dump), this campus sits here after filters:

Counts come from leftover unique strings after the last live leftover-site batch plus unique NCT IDs in /workspace/five-trials/ctgov-raw/all_interventional.jsonl (17497 studies; ClinicalTrials.gov LATAM facility sweep, API pull 1 September 2026, 6:32 PM ET; dump confirmed 1 September 2026). Alias strings are listed separately. We do not publish a unique-study union across alias strings. We do not invent a global CSV rank. We do not invent unpublished CMS IDs. DEVICE FIH evidence for this campus is thin — one older feasibility row. Other Chile rows for this campus are mostly non-DEVICE (behavioral, drug, biologic, diagnostic). We do not inflate DEVICE FIH volume. Registry ranking is not a bioaccess® claim that we ran any of these studies.

• Hospital del Trabajador (Santiago, Chile) — sole DEVICE / feasibility title cited here: NCT00823251 (IlluminOss Hand Fracture International Clinical Feasibility Study; COMPLETED).

Aliases seen on the registry family: Hospital del Trabajador, Hospital del Trabajador de Santiago, Hospital del Trabajador de la Asociación Chilena de Seguridad. List separately. Do not invent a deep FIH/EFS portfolio from non-DEVICE rows.

That single NCT ID is facility evidence, not a count of first-in-human device programs bioaccess® ran. It is how a sponsor searching the hospital name lands on a campus without landing on an operator.

We cite the ID as facility evidence. We will not invent a PI. We will not claim bioaccess® ran it. No live bioaccess® case-study page names this hospital as a client site.

That is the leak: a founder searching Hospital del Trabajador Santiago first-in-human finds an IlluminOss clinical-feasibility DEVICE row without finding ISP. A named hospital campus is still a site. An NCT location row is not a CRO. A trauma-hospital brand story is still not a CRO — and a thin DEVICE portfolio is not a deep FIH pipeline.

The site is the site. The CRO is the operator.

A named hospital can provide rooms, coordinators, institutional ethics calendars, and investigators who already appear on NCT rows. That is necessary. It is not sufficient for a first-in-human medical device study a U.S. board expects to survive FDA review.

What the hospital can typically do when a sponsor “goes direct”:

• Discuss investigator interest and whether a protocol can sit in an existing service line.
• Share institutional ethics-committee calendars and hospital research rules.
• Quote visit, staffing, and local procedure costs for the cases they will physically run.

What the hospital is not built to own for an investigational device:

• ISP. Instituto de Salud Pública (ISP) authorizes studies and investigational-device import in Chile. Live Chile blogs already put a typical ISP review in a band of about 30 business days. Commercial ISP registration (30–90 days) is a different file. An Ethical-Scientific Committee under Law 20.120 still has to sit. A hallway conversation on this campus is not that stack. We will not invent PAHO/WHO Level 4 standing for ISP. A hallway conversation at Hospital del Trabajador is not a Clínica Colonial file, not a Hospital FACH file, and not a Clínica INDISA file.
• Investigational import. Ethics letter, investigator’s brochure, and an importation permit — end-to-end work, not a PI email. See importer of record for clinical trial devices in Latin America.
• Clinical trial insurance. Required. We will not invent a campus-only premium here.
• ISO 14155 monitoring, EDC, SAE reporting, and the TMF. The site may run visits. The CRO runs the quality system the FDA will later ask about.
• The 21 CFR 812.28 package. Foreign data is eligible for FDA submission and review after GCP / ethics documentation. Eligibility is not clearance, and a site MSA does not produce it.
• Multi-country optionality. If enrollment or the indication later needs another Latin American country, a single-hospital MSA will not stretch.

Going direct to this campus is how you confirm a room. It is not how you open an investigational file.

How ISP actually works (the short version)

Use clinical-trials-chile. Instituto de Salud Pública (ISP) authorizes studies and investigational-device import. Live Chile blogs already put a typical ISP review in a band of about 30 business days. Commercial ISP registration in a 30–90 day band is a different file — do not put trial authorization and commercial registro on one Gantt labeled “Chile.” An Ethical-Scientific Committee under Law 20.120 still has to sit. We will not invent PAHO/WHO Level 4 standing for ISP on this page.

Ask for a protocol-specific calendar. A hospital email is not ISP clearance. bioaccess® manages the file. That is CRO work, not site work.

All bioaccess® device protocols in this country are run under ISO 14155 and the Declaration of Helsinki. Data is designed to be eligible for FDA submission and review under 21 CFR 812.28 on a case-by-case basis — not a guarantee of clearance or approval. See OUS FIH and FDA IDE.

Do not smear the hospital

Hospital del Trabajador Santiago is a serious named Chilean trauma/occupational campus on the public registry — IlluminOss clinical-feasibility DEVICE evidence under Hospital del Trabajador is real, not a punchline. The portfolio is thin. Do not invent a PI. Do not inflate DEVICE FIH volume from non-DEVICE rows. Use the site when the protocol fits. Hire the operator.

What the CRO still does after you have the campus on a slide

1. Regulatory-fit, not tourism. This geography is sourced. One campus is not automatically the right room for every indication. bioaccess® still runs trials in Colombia and the rest of the platform.
2. Protocol, IB, ICF, insurance, and the ISP / ethics packet.
3. Importer of record and device accountability.
4. Site activation that is more than a tour: contracts, training, investigational product, EDC, monitoring plan. Activate this campus only if it fits the protocol.
5. ISO 14155 monitoring and the 21 CFR 812.28 narrative so the dataset is built for a later Pre-Sub, IDE, 510(k), De Novo, PMA, or HDE — eligibility, not a promise of FDA action.

The firm was founded in 2010. That is the operator layer around a campus string.

Colombia is still on the map

Public line, unchanged: bioaccess® still runs clinical trials in Colombia — local entity, Miami headquarters, own CRO in Colombia. Because INVIMA clinical-trial approval timelines have become unpredictable, bioaccess® does not currently recommend Colombia for new FIH trial execution. INVIMA commercial registration remains. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K as published on clinical-trials-panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.

Frequently asked questions

Can I contract Hospital del Trabajador Santiago directly for a device FIH?

You can try. The hospital can discuss investigator interest, local visit costs, and ethics calendars. It cannot, by ranking on ClinicalTrials.gov, become your ISP applicant, importer of record, insurer, ISO 14155 monitor, or 21 CFR 812.28 packager. Contract the CRO, then let the CRO activate the site if the site fits.

Did bioaccess® run the NCT ID listed here?

No public bioaccess® case-study page names this hospital. We will not invent that claim. This page intercepts the search; it does not claim the study.

Is this the same page as Hospital FACH or Clínica INDISA?

No. hospital-fach-santiago-fih and clinica-indisa-santiago-fih are distinct Santiago campuses. This page is Hospital del Trabajador / Hospital del Trabajador de Santiago / Asociación Chilena de Seguridad hospital only.

Did bioaccess® run NCT00823251?

No. We cite it as facility evidence. We will not invent a sponsor or a PI. We will not claim bioaccess® ran this study. DEVICE FIH evidence here is thin — one COMPLETED IlluminOss clinical-feasibility row.

Next step

If the search that brought you here was this campus, start as the operator: contact bioaccess® or book from First-in-Human CRO. Santiago siblings (do not merge): Hospital FACH Santiago, Clínica INDISA Santiago, Clínica Colonial Santiago.

Julio G. Martinez-Clark, CEO · bioaccess®